Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16762042 | 1.00 | CACNA1B (0.41) | CACNA1BPPARGPPARAMAPTKMT2A | |
| SCHEMBL29627346 | 0.90 | MAPT (0.53) | MAPTITGB3ITGA2B | |
| SCHEMBL21715297 | 0.90 | MAPT (0.53) | MAPTITGB3ITGA2B | |
| SCHEMBL17009235 | 0.88 | CTSK (0.48) | CACNA1BPPARGPPARACTSKHDAC1 | |
| SCHEMBL20211087 | 0.88 | CTSK (0.48) | CACNA1BPPARGPPARACTSKHDAC1 | |
| SCHEMBL6123047 | 0.87 | CACNA1B (0.43) | CACNA1BPPARGPPARAITGB3ITGA2B | |
| SCHEMBL28820385 | 0.86 | L3MBTL1 (0.42) | CACNA1BPPARGPPARAMAPTKMT2A | |
| SCHEMBL15238498 | 0.86 | L3MBTL1 (0.42) | CACNA1BPPARGPPARAMAPTKMT2A | |
| SCHEMBL16762203 | 0.83 | CACNA1B (0.47) | CACNA1BPPARGPPARAITGB3ITGA2B | |
| SCHEMBL17397484 | 0.82 | PPARA (0.40) | CACNA1BPPARGPPARAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | 7 HILLS PHARMA INC. | 2021-05-20 | — | — | US | claimed |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-21 | — | — | US | claimed |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | claimed |
| US-10709780-B2 | Integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | claimed |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | 7 Hills Pharma LLC (US) | 2020-02-20 | — | — | US | claimed |
| EP-2640721-B1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | CD47, ITGA1, ITGA2B | CACNA1B 3420/4885PPARG 880/4885PPARA 1037/4885 |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | CD47, ITGA1, ITGAM | CACNA1B 3112/4885PPARG 807/4885PPARA 962/4885 |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA2 | CACNA1B 2536/4885PPARG 1211/4885PPARA 1300/4885 |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | ITGB7, ITGA1, ITGAL | CACNA1B 1234/4885PPARG 874/4885PPARA 1085/4885 |
| US-10709780-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | CACNA1B 2014/4885PPARG 1241/4885PPARA 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.